HealthLupin recalls over 6 lakh bottles of hypertension drug...

Lupin recalls over 6 lakh bottles of hypertension drug in U.S.: USFDA

-

spot_img


The USFDA reports states that the affected lot is manufactured at Lupin’s Goa-based manufacturing facility. File
| Photo Credit: Reuters

Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the U.S. due to deviation from current good manufacturing practices (CGMP), according to the U.S. health regulator.

As per its latest Enforcement Report, U.S. Food and Drug Administration (USFDA), stated that Dr. Reddy’s Laboratories is also recalling a product in the U.S. due to a manufacturing issue.

Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of Mumbai-based Lupin, is recalling 6,16,506 bottles of Ramipril capsules in strengths of 2.5 mg, 5 mg and 10 mg, the U.S. health regulator said.

The affected lot is manufactured at Lupin’s Goa-based manufacturing facility, it stated.

The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets, it said.

The U.S. health regulator noted that the company is undertaking Class II voluntary recall due to “CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor.” Lupin Pharmaceuticals Inc. initiated the recall on October 23 this year.

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

In a separate listing, USFDA stated that a U.S.-based unit of Dr. Reddy’s Laboratories is recalling 3,416 Made in India bottles of IBU (ibuprofen) 600 mg tablets in the U.S.

Princeton (NJ) based Dr. Reddy’s Laboratories, Inc initiated the Class III recall due to “Failed Tablet/Capsule Specifications,” USFDA said.

The company initiated the voluntary recall on October 29.

As per the USFDA, a Class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.”



Source link

Latest news

On Its Longevity Quest, LVMH’s R&D Teams With Integrated Biosciences

PARIS – As part of its quest for longevity, LVMH Moët Hennessy Louis Vuitton’s research-and-development division and Integrated Biosciences...

Romania and Bulgaria to join EU’s Schengen free movement area

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly...

Addressing inequities in cardiovascular drug access

A new study assessing provincial and...

Ganni Pre-Fall 2025 Collection | Vogue

It’s been a banner year for Ganni, which presented its spring 2025 collection in Paris. This wasn’t a...
spot_img

Conservative US commentator Candace Owens granted NZ visa after government intervention | New Zealand

The controversial US commentator Candace Owens has been granted a visa to enter New Zealand after the government...

Understanding how angiogenesis contributes to drug resistance in breast cancer

Breast cancer, the most common cancer...

Must read

On Its Longevity Quest, LVMH’s R&D Teams With Integrated Biosciences

PARIS – As part of its quest for longevity,...

Romania and Bulgaria to join EU’s Schengen free movement area

Unlock the Editor’s Digest for freeRoula Khalaf, Editor...
spot_img

You might also likeRELATED
Recommended to you